Last updated: July 3, 2026
Bausch Health US, LLC sued Mylan Pharmaceuticals Inc. in the Northern District of West Virginia in 1:20-cv-00046, asserting patent infringement tied to Mylan’s FDA approval path for a Bausch-branded product. The case posture and the asserted patent set drive both near-term launch risk and the survivability of Mylan’s generic strategy.
What is the case docket for Bausch Health US, LLC v. Mylan Pharmaceuticals Inc. (1:20-cv-00046)?
Answer: 1:20-cv-00046 is an N.D. West Virginia patent-infringement action brought by Bausch Health US, LLC against Mylan Pharmaceuticals Inc. in 2020, framed under the Hatch-Waxman structure (Orange Book-listed patents and FDA ANDA regulatory events).
Court, parties, and procedural track
- Court: United States District Court for the Northern District of West Virginia
- Case number: 1:20-cv-00046
- Plaintiff: Bausch Health US, LLC
- Defendant: Mylan Pharmaceuticals Inc.
- Filing year: 2020
- Litigation type (implied): Hatch-Waxman-style patent infringement tied to an ANDA submission and Orange Book patents
What patents were asserted in Bausch Health US, LLC v. Mylan (1:20-cv-00046)?
Answer: This cannot be stated from the information provided. A litigation summary must list asserted patent numbers, claims, and infringement theories to be complete and decision-grade.
Why asserted patents are essential for analysis
- Claim construction outcome materially changes infringement probability.
- Statement of “invalidity grounds” (35 USC §102/103/112, obviousness, written description, indefiniteness) determines whether Mylan can preserve a noninfringing route.
- Settlement and injunction scope hinge on the specific patent family.
What relief did Bausch Health seek in the complaint (injunction, damages, fees)?
Answer: This cannot be stated from the information provided. A correct summary must specify the requested relief (temporary restraining order/preliminary injunction, permanent injunction, damages, costs, attorneys’ fees, and any carve-outs).
Key relief categories that determine business impact
- Injunction scope: launch-blocking vs. limited to product strength/formulation.
- Stay status: whether the court stayed final judgment pending PTAB or other events.
- Entitlement to fees: fee-shifting can change settlement leverage.
When did the case get filed, and what were the key milestones?
Answer: This cannot be stated from the information provided. A business-grade timeline requires dates for:
- complaint filing
- answer and invalidity defenses
- claim construction scheduling
- summary judgment motions
- trial dates or non-trial resolution dates
- final judgment entry
How strong is Bausch’s patent estate in this specific case?
Answer: This cannot be evaluated without the asserted patent list, priority/filing dates, prosecution history, and claim scope.
Strength drivers that usually determine outcomes in ANDA litigation
- Earliest priority and remaining life (expiration + pediatric exclusivity effects)
- Whether claims are method-of-use, formulation, or device-related
- Whether patents have a history of §112 rejections
- Claim breadth vs. prior art overlap
- Whether the alleged infringing product matches claim limitations
What are the generic entry risks for Mylan if Bausch’s patents expire first?
Answer: This cannot be stated from the information provided. Entry risk depends on:
- the effective statutory expiration and any exclusivity extensions
- whether the asserted patents are valid and enforceable
- whether Mylan’s product design avoids the limitations in the asserted claims
What does the FDA regulatory posture imply for this litigation?
Answer: This cannot be stated from the information provided. A correct analysis must tie the infringement action to:
- the Orange Book patent list
- the FDA approval pathway (ANDA vs. 505(b)(2))
- the specific FDA submission certification type (Paragraph I, II, III, IV)
- any FDA refusals, amendments, or approval dates
Has Mylan asserted defenses or counterclaims (invalidity, noninfringement, carve-outs)?
Answer: This cannot be stated from the information provided. A litigation analysis must identify:
- invalidity theories (anticipation, obviousness, subject matter eligibility, §112)
- noninfringement positions (formulation differences, manufacturing process differences, label-driven method-of-use differences)
- any “noninfringement by design” or “design-around” evidence
What did the court rule in Bausch Health v. Mylan (motions to dismiss, claim construction, summary judgment)?
Answer: This cannot be stated from the information provided. Court rulings define the outcome probability:
- Markman/claim construction results
- grant/denial of preliminary injunction
- summary judgment on infringement or invalidity
- final judgment or dismissal basis (settlement, covenant-not-to-sue, procedural defect)
Was there a settlement or consent judgment?
Answer: This cannot be stated from the information provided. Settlement terms determine:
- date of generic launch (if any)
- scope limits (strength, NDC, dosage form)
- payment structure (typically allowed under settlement frameworks)
- dismissal with prejudice vs. without prejudice
- any stipulation affecting future patent enforcement
How does this case compare with other Bausch vs. generic litigations in the same product category?
Answer: This cannot be done from the information provided. A comparison requires knowing:
- which Bausch product is at issue
- whether the same patent families recur across cases
- which generic entities were defendants and how courts ruled
Which jurisdictions and patents could still matter after 1:20-cv-00046 resolves?
Answer: This cannot be stated from the information provided. Patent enforcement after a case depends on:
- whether there are related continuations or later-filed patents in the same family
- whether Bausch can sue for additional infringement under separate NDA/ANDA approvals
- whether there are appeals to the Federal Circuit
- whether other defendants are at risk under similar ANDA certifications
Key Takeaways
- 1:20-cv-00046 is a Bausch Health US, LLC v. Mylan Pharmaceuticals Inc. patent-infringement case in the Northern District of West Virginia with Hatch-Waxman implications.
- A decision-grade litigation summary requires the asserted patent numbers, FDA/Orange Book certifications, and the procedural disposition, which are not provided in the input.
- Without those case-specific facts, any statement about patent strength, timelines, or launch risk would be incomplete.
FAQs
- What does a Paragraph IV certification mean in a Bausch vs. Mylan ANDA case?
- How do claim-construction outcomes typically affect infringement findings in ANDA patent suits?
- What invalidity grounds are most common in Hatch-Waxman litigation for formulation and method-of-use patents?
- How do settlement terms usually structure generic launch dates and scope limitations?
- What role does PTAB review play in staying or influencing ANDA patent litigation outcomes?
References
- United States District Court for the Northern District of West Virginia, Case 1:20-cv-00046 (Bausch Health US, LLC v. Mylan Pharmaceuticals Inc.).
